WO2010060055A1 - Prédiction du risque et du succès d’un traitement du cancer - Google Patents

Prédiction du risque et du succès d’un traitement du cancer Download PDF

Info

Publication number
WO2010060055A1
WO2010060055A1 PCT/US2009/065570 US2009065570W WO2010060055A1 WO 2010060055 A1 WO2010060055 A1 WO 2010060055A1 US 2009065570 W US2009065570 W US 2009065570W WO 2010060055 A1 WO2010060055 A1 WO 2010060055A1
Authority
WO
WIPO (PCT)
Prior art keywords
recurrence
cancer
genes
expression
likelihood
Prior art date
Application number
PCT/US2009/065570
Other languages
English (en)
Inventor
Anil Potti
Katherine Garman
Joseph R. Nevins
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2010060055A1 publication Critical patent/WO2010060055A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

La présente invention concerne des procédés pour prédire la probabilité de récurrence d’un cancer en utilisant des profils d’expression génique. La présente invention concerne en outre des procédés pour développer des plans de traitement pour des individus ayant un cancer. L’invention concerne également des kits comprenant des puces à ADN et des instructions pour prédire la récurrence d’un cancer et un support lisible sur ordinateur comprenant des informations de récurrence.
PCT/US2009/065570 2008-11-21 2009-11-23 Prédiction du risque et du succès d’un traitement du cancer WO2010060055A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11701008P 2008-11-21 2008-11-21
US61/117,010 2008-11-21
US11926108P 2008-12-02 2008-12-02
US61/119,261 2008-12-02

Publications (1)

Publication Number Publication Date
WO2010060055A1 true WO2010060055A1 (fr) 2010-05-27

Family

ID=42198539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065570 WO2010060055A1 (fr) 2008-11-21 2009-11-23 Prédiction du risque et du succès d’un traitement du cancer

Country Status (1)

Country Link
WO (1) WO2010060055A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
US10196691B2 (en) 2011-01-25 2019-02-05 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US10214777B2 (en) 2010-09-15 2019-02-26 Almac Diagnostics Limited Molecular diagnostic test for cancer
CN112365948A (zh) * 2020-10-27 2021-02-12 沈阳东软智能医疗科技研究院有限公司 癌症分期预测系统
CN112599190A (zh) * 2020-12-17 2021-04-02 重庆大学 一种基于混合分类器来识别耳聋相关基因的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124836A1 (fr) * 2005-05-13 2006-11-23 Duke University Signatures d'expression genetique pour la deregulation de mecanismes oncogeniques
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
WO2007142936A2 (fr) * 2006-05-30 2007-12-13 Duke University Prédiction de la récurrence de tumeurs cancéreuses pulmonaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124836A1 (fr) * 2005-05-13 2006-11-23 Duke University Signatures d'expression genetique pour la deregulation de mecanismes oncogeniques
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
WO2007142936A2 (fr) * 2006-05-30 2007-12-13 Duke University Prédiction de la récurrence de tumeurs cancéreuses pulmonaires

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214777B2 (en) 2010-09-15 2019-02-26 Almac Diagnostics Limited Molecular diagnostic test for cancer
US10378066B2 (en) 2010-09-15 2019-08-13 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
US10196691B2 (en) 2011-01-25 2019-02-05 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
CN112365948A (zh) * 2020-10-27 2021-02-12 沈阳东软智能医疗科技研究院有限公司 癌症分期预测系统
CN112365948B (zh) * 2020-10-27 2023-07-18 沈阳东软智能医疗科技研究院有限公司 癌症分期预测系统
CN112599190A (zh) * 2020-12-17 2021-04-02 重庆大学 一种基于混合分类器来识别耳聋相关基因的方法
CN112599190B (zh) * 2020-12-17 2024-04-05 重庆大学 一种基于混合分类器来识别耳聋相关基因的方法

Similar Documents

Publication Publication Date Title
Lu et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
AU2015289758B2 (en) Methods for evaluating lung cancer status
Wozniak et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States
JP5089993B2 (ja) 乳癌の予後診断
US8211643B2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20130332083A1 (en) Gene Marker Sets And Methods For Classification Of Cancer Patients
Cao et al. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression
WO2007038792A2 (fr) Traitements anticancereux individualises
US11788148B2 (en) Prognostic and treatment response predictive method
WO2006119593A1 (fr) Pronostic algorithmique du cancer base sur les genes gene-based algorithmic cancer prognosis
JP2015536667A (ja) 癌のための分子診断検査
JP2016536001A (ja) 肺がんのための分子診断試験
US20090177450A1 (en) Systems and methods for predicting response of biological samples
EP2419540B1 (fr) Procédés et signature d'expression génétique pour évaluer l'activité de la voie ras
JP2010502227A (ja) 生物学的経路の遺伝子発現分析を用いたリンパ節陰性の原発性乳がんの遠隔転移を予測する方法
Park et al. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma
Chen et al. Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis
WO2010060055A1 (fr) Prédiction du risque et du succès d’un traitement du cancer
Thorsteinsson et al. Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature
Wan et al. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma
US11851713B2 (en) Assessing colorectal cancer molecular subtype and uses thereof
Guo et al. A predictive 7-gene assay and prognostic protein biomarkers for non-small cell lung cancer
Guo et al. A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers
CN115141887A (zh) 基于分泌细胞富集特征的结肠癌预后及辅助化疗获益的评分模型、构建方法及应用
US20230106465A1 (en) 7-Gene Prognostic and Predictive Assay for Non-Small Cell Lung Cancer in Formalin Fixed and Paraffin Embedded Samples

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828361

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09828361

Country of ref document: EP

Kind code of ref document: A1